Prognosis of pulmonary fibrosis presenting with a usual interstitial pneumonia pattern on computed tomography in patients with myeloperoxidase anti-neutrophil cytoplasmic antibody-related nephritis: a retrospective single-center study

Table 2 Clinical characteristics of patients with MPO-ANCA nephritis with a UIP pattern and patients with IPF

Characteristics	MPO-ANCA nephritis with UIP pattern	IPF	p-value
Patients	31	32
Age, years	74 (58–88)	70 (58–87)	0.083
Male	16	29	0.0021
Smoking history
Never/former or current	16/15	6/26	0.0068
Respiratory symptoms
Cough	19	16	0.37
Dyspnea	12	18	0.16
None	9	6	0.34
Serological testing
LDH, U/L	225.5 ± 64.9	236.2 ± 45.1	0.35
KL-6, IU/mL	1298 ± 914.8	1341 ± 853.5	0.73
Treatment
None	2 (6.5)	0 (0.0)
Immunosuppressive agents	28 (90.0)	0 (0.0)
Antifibrotic agents	1 (3.2)	32 (100.0)
	nintedanib	nintedanib n = 14
	300 mg/day	300 mg/day n = 4
		200 mg/day n = 10
		pirfenidone n = 18
		1800 mg/day n = 3
		1200 mg/day n = 11
		600 mg/day n = 4

Data are presented as n, median (range), mean ± standard deviation, or n (%)
MPO-ANCA nephritis myeloperoxidase anti-neutrophil cytoplasmic antibody-related nephritis, UIP usual interstitial pneumonia, IPF idiopathic pulmonary fibrosis, LDH lactate dehydrogenase, KL-6 Krebs von den Lungen-6

ISSN: 1471-2466